Glaxosmithkline Phar

₹2241.8 -23.3 | 1%

WEBSITE BSE:500660 NSE : GLAXOSMITH 26 Dec, 16:01

Market Cap ₹37977 Cr.

Stock P/E 64.4

P/B 22.7

Current Price ₹2241.8

Book Value ₹ 98.9

Face Value 10

52W High ₹3088

Dividend Yield 1.43%

52W Low ₹ 1764.9

Edit Ratio

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

GlaxoSmithKline Pharmaceuticals Ltd is a pharmaceutical enterprise. The Company is engaged in the business of manufacturing, distributing, and trading in prescription drugs. It manufactures medicinal materials used in the manufacture of prescription drugs, inclusive of antibiotics, endocrine products, basic nutrients; opium derivatives; sulpha tablets; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically natural sugar. It gives various prescription drugs, vaccines, and consumer healthcare products. Its medication portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio consists of Ambirix, Cervarix, Fendrix, and Havrix. The Company's products consist of Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health merchandise include Sensodyne, parodontax and Polident. Its manufacturing unit is at Nashik.

Glaxosmithkline Phar Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Glaxosmithkline Phar Quarterly Results

#(Fig in Cr.)	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018
Net Sales	784	607	836	704	749
Other Income	15	14	10	12	18
Total Income	799	621	846	716	767
Total Expenditure	647	587	644	562	594
Operating Profit	152	33	202	154	173
Interest	0	0	0	0	0
Depreciation	8	8	8	13	9
Exceptional Income / Expenses	26	13	5	0	0
Profit Before Tax	170	38	199	140	164
Provision for Tax	57	12	69	51	58
Profit After Tax	113	26	130	90	106
Adjustments	-113	-26	-130	-90	-106
Profit After Adjustments	0	0	0	0	0
Adjusted Earnings Per Share	6.7	1.6	7.7	5.3	6.2

Glaxosmithkline Phar Profit & Loss

#(Fig in Cr.)	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	2591	3346	2826	2903	2872	3129	3225	2920	3218	3216	3407	2896
Other Income	246	258	122	72	54	101	78	110	76	102	123	54
Total Income	2837	3604	2948	2975	2925	3230	3302	3031	3294	3318	3531	2950
Total Expenditure	2114	2777	2349	2483	2363	2522	2566	2323	2462	2417	2507	2387
Operating Profit	723	826	599	492	562	708	736	708	832	901	1024	562
Interest	0	0	0	0	0	1	6	4	2	2	2	0
Depreciation	20	25	25	26	38	49	83	79	68	66	70	38
Exceptional Income / Expenses	26	-52	2	46	18	5	-324	-173	12	-1	-144	18
Profit Before Tax	729	749	576	511	542	664	322	453	773	832	809	541
Provision for Tax	227	277	201	174	190	238	212	167	397	228	224	190
Profit After Tax	502	472	375	337	352	425	110	287	377	605	585	352
Adjustments	0	0	0	0	0	0	0	71	1314	3	0	-352
Profit After Adjustments	502	472	375	337	352	425	110	358	1691	608	585	0
Adjusted Earnings Per Share	29.6	27.8	22.1	19.9	20.8	25.1	6.5	16.9	22.2	35.7	34.5	20.8

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	6%	5%	2%	3%
Operating Profit CAGR	14%	13%	8%	4%
PAT CAGR	-3%	27%	7%	2%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	27%	9%	7%	4%
ROE Average	33%	26%	20%	20%
ROCE Average	46%	40%	33%	32%

Glaxosmithkline Phar Balance Sheet

#(Fig in Cr.)	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	2017	1852	2205	2028	2080	2142	1840	1497	2678	1753	1784
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	4	3	2	1	1	0	0	0	0	0	0
Other Non-Current Liabilities	154	193	189	3639	2572	2835	181	179	158	124	107
Total Current Liabilities	883	1106	575	878	2945	2801	1002	1319	1674	1317	1511
Total Liabilities	3058	3153	2970	6546	7598	7778	3023	2995	4510	3195	3402
Fixed Assets	100	123	204	253	323	430	757	386	329	329	320
Other Non-Current Assets	356	465	618	4483	3763	4007	509	439	510	399	316
Total Current Assets	2602	2565	2142	1809	3507	3338	1757	1991	3671	2467	2766
Total Assets	3058	3153	2970	6546	7598	7778	3023	2995	4510	3195	3402

Glaxosmithkline Phar Cash Flow

#(Fig in Cr.)	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	137	93	115	114	138	199	98	98	405	281	30
Cash Flow from Operating Activities	267	341	138	232	475	411	491	595	820	488	579
Cash Flow from Investing Activities	198	178	499	303	-107	-154	-63	408	-420	805	15
Cash Flow from Financing Activities	-490	-497	-638	-511	-307	-358	-428	-696	-524	-1544	-561
Net Cash Inflow / Outflow	-25	22	-1	25	61	-102	0	307	-124	-251	32
Closing Cash & Cash Equivalent	112	115	114	138	199	98	98	405	281	30	62

Glaxosmithkline Phar Ratios

#	Dec 2013	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	29.63	27.84	22.11	19.88	20.78	25.11	6.5	16.92	22.23	35.7	34.51
CEPS(Rs)	30.8	29.34	23.58	21.44	23.02	27.98	11.38	21.56	26.25	39.58	38.63
DPS(Rs)	25	62.5	50	15	35	20	40	30	90	32	32
Book NAV/Share(Rs)	119.07	109.3	130.14	119.73	122.78	126.47	108.62	88.37	158.06	103.58	105.85
Core EBITDA Margin(%)	17.91	16.48	16.87	14.02	16.84	19.39	19.58	19.16	21.39	22.63	24.09
EBIT Margin(%)	27.39	21.71	20.39	17.08	17.95	21.23	9.78	14.64	21.94	23.61	21.69
Pre Tax Margin(%)	27.37	21.69	20.38	17.07	17.94	21.21	9.59	14.53	21.89	23.56	21.64
PAT Margin (%)	18.84	13.67	13.25	11.25	11.66	13.6	3.27	9.19	10.66	17.12	15.64
Cash Profit Margin (%)	19.58	14.4	14.13	12.13	12.92	15.15	5.73	11.71	12.59	18.98	17.51
ROA(%)	16.56	15.19	12.23	7.08	4.98	5.53	2.04	9.53	10.04	15.7	17.73
ROE(%)	24.92	24.38	18.47	15.91	17.14	20.15	5.53	17.18	18.04	27.29	32.96
ROCE(%)	36.16	38.65	28.38	24.14	26.36	31.45	16.51	27.37	37.15	37.66	45.85
Receivable days	14.54	10.4	14.65	18.12	19.21	15.6	11.96	18.45	21.73	20.54	20.23
Inventory Days	42.77	37.61	57.5	57.72	55.96	57.56	52.62	58.87	53.51	49.1	46.48
Payable days	91.55	80.56	87.05	78.43	114.5	122.09	105.65	117.18	141.33	142.2	146.15
PER(x)	50.51	61.11	85.96	68.79	50.18	51.77	191.68	85.11	74.81	37.1	56.3
Price/Book(x)	12.57	15.57	14.6	11.42	8.49	10.28	11.46	16.3	10.52	12.78	18.36
Dividend Yield(%)	1.67	1.84	1.32	1.1	1.68	1.54	3.21	2.08	5.41	2.42	1.65
EV/Net Sales(x)	9	8.05	10.9	7.68	5.71	6.67	6.21	7.96	7.99	6.62	9.35
EV/Core EBITDA(x)	32.24	32.59	51.45	45.3	29.16	29.47	27.21	32.83	30.88	23.62	31.11
Net Sales Growth(%)	-3.02	29.13	-15.53	2.72	-1.08	8.94	3.07	-9.43	10.17	-0.04	5.94
EBIT Growth(%)	-13.84	2.66	-23.06	-11.28	5.95	22.61	-50.5	38.9	69.77	7.58	-2.8
PAT Growth(%)	-13.06	-6.02	-20.59	-10.08	4.52	20.85	-74.13	160.5	31.35	60.58	-3.31
EPS Growth(%)	-13.06	-6.02	-20.59	-10.08	4.52	20.84	-74.13	160.5	31.35	60.58	-3.31
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	2.95	2.32	3.73	2.06	1.19	1.19	1.75	1.51	2.19	1.87	1.83
Quick Ratio(x)	2.56	1.99	2.82	1.58	1.02	1.02	1.27	1.11	1.89	1.54	1.49
Interest Cover(x)	2205.05	1597.21	1368.05	2045.32	2865.01	1198.38	51.9	129.34	389.7	460.68	450.79
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Glaxosmithkline Phar Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	75	75	75	75	75	75	75	75	75	75
FII	2.16	2.17	2.29	2.28	2.41	2.5	2.92	3.48	4.02	4.36
DII	10.65	10.54	10.28	10.3	10.25	10.02	8.65	7.9	7.5	7.33
Public	12.19	12.29	12.43	12.43	12.35	12.49	13.43	13.62	13.48	13.3
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71	12.71
FII	0.37	0.37	0.39	0.39	0.41	0.42	0.5	0.59	0.68	0.74
DII	1.8	1.78	1.74	1.74	1.74	1.7	1.46	1.34	1.27	1.24
Public	2.06	2.08	2.11	2.11	2.09	2.12	2.27	2.31	2.28	2.25
Others	0	0	0	0	0	0	0	0	0	0
Total	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94	16.94

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 26%
Company is almost debt free.

Cons

Debtor days have increased from 142.2 to 146.15days.
Stock is trading at 22.7 times its book value.
The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glaxosmithkline Phar News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Glaxosmithkline Phar

Add Watchlist

Glaxosmithkline Phar Research see more...

Overview Inc. Year: 1924Industry: Pharmaceuticals & Drugs

Glaxosmithkline Phar Share Price

Alert Data

Quarterly Price

Peer Comparison

Glaxosmithkline Phar Quarterly Results

Glaxosmithkline Phar Profit & Loss

Growth Rates

Glaxosmithkline Phar Balance Sheet

Glaxosmithkline Phar Cash Flow

Glaxosmithkline Phar Ratios

Glaxosmithkline Phar Shareholding Pattern

Glaxosmithkline Phar News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!